EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T

Natalia Ruggeri Barbaro, Theodore Drashansky, Kristina Tess, Mansour Djedaini, Robert Hariri, Shuyang He, William van der Touw, Kathy Karasiewicz iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Natalia Ruggeri Barbaro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Celularity Inc, Florham Park, New Jersey, USA. Hauptthemen laut MEDLINE: Placenta, Cytokines, Immunotherapy, Adoptive, Leukocytes, Mononuclear. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Celularity Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR)-T cell quality and stemness are associated with responsiveness, durability, and memory formation, which benefit clinical responses. Autologous T cell starting material across patients with cancer is variable and CAR-T expansion or potency can fail during manufacture. Thus, strategies to develop allogeneic CAR-T platforms including the identification and expansion of T cell subpopulations that correspond with CAR-T potency are an active area of investigation. Here, we compared CAR-T cells generated from healthy adult peripheral blood T cells versus placental circulating T (P-T) cells.

Methods

CAR-T cells from healthy adult peripheral blood mononuclear cells (PBMCs) and P-T cells were generated using the same protocol. CAR-T cells were characterized in detail by a combination of multiparameter flow cytometry, functional assays, and RNA sequencing. In vivo antitumor efficacy and persistence of CAR-T cells were evaluated in a Daudi lymphoma xenograft model.

Results

P-T cells possess stemness advantages compared with T cells from adult PBMCs. P-T cells are uniformly naïve prior to culture initiation, maintain longer telomeres, resist immune checkpoint upregulation, and resist further differentiation compared with PBMC T cells during CD19 CAR-T manufacture. P-T CD19 CAR-T cells are equally cytotoxic as PBMC-CD19 CAR-T cells but produce less interferon gamma in response to lymphoma. Transcriptome analysis shows P-T CD19 CAR-T cells retain a stem-like gene signature, strongly associate with naïve T cells, an early memory phenotype, and a unique CD4 T cell signature compared with PBMC-CD19 CAR-T cells, which enrich for exhaustion and stimulated memory T cell signatures. Consistent with functional data, P-T CD19 CAR-T cells exhibit attenuated inflammatory cytokine and chemokine gene signatures. In a murine in vivo model, P-T CD19 CAR-T cells eliminate lymphoma beyond 90 days. PBMC-CD19 CAR-T cells provide a non-durable benefit, which only delays disease onset.

Conclusion

We identified characteristics of T cell stemness enriched in P-T CD19 CAR-T which are deficient in PBMC-derived products and translate into response durability in vivo. Our findings demonstrate that placental circulating T cells are a valuable cell source for allogeneic CAR-T products. Stemness advantages inherent to P-T cells translate to in vivo persistence advantages and long-term durable activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlacentaCytokinesImmunotherapy, AdoptiveLeukocytes, MononuclearReceptors, Chimeric AntigenT-LymphocytesHumansFemaleAnimalsMicePregnancyAdultXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Adoptive cell therapy - ACTChimeric antigen receptor - CART cell

Substanzen

CytokinesReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Celularity Inc, Florham Park, New Jersey, USA.
  • Celularity Inc, Florham Park, New Jersey, USA kathy.karasiewicz@celularity.com.

ORCID-Profile: Kathy Karasiewicz

Förderung

  • Celularity Inc.

Zitieren

APA

Ruggeri Barbaro, N., Drashansky, T., Tess, K., Djedaini, M., Hariri, R., He, S., van der Touw, W., & Karasiewicz, K. (2024). Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008656

Vancouver

Ruggeri Barbaro N, Drashansky T, Tess K, Djedaini M, Hariri R, He S, et al. Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008656

BibTeX
@article{RuggeriBarbaro2024,
  author = {Ruggeri Barbaro, Natalia and Drashansky, Theodore and Tess, Kristina and Djedaini, Mansour and Hariri, Robert and He, Shuyang and van der Touw, William and Karasiewicz, Kathy},
  title = {Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008656}
}
Kostenlos starten →